Delhi HC seeks Dr Reddy's reply in Novo patent dispute
The Delhi High Court has directed Dr. Reddy's Labs to respond to Novo Nordisk's injunction petition concerning its weight-loss drug, semaglutide (Wegovy). Novo Nordisk alleges patent infringement, prompting the court's action. An IP expert suggests Dr. Reddy's Labs may need to justify its semaglutide exports, as Novo Nordisk's patent is set to expire in March of next year.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
4 hours ago
- Economic Times
Weight-loss drug Mounjaro crosses Rs 100 crore sales in 4 months
Synopsis The drug clocked Rs 47-crore sales in July, double its June figure, according to data from prescriptions tracker PharmaTrac. If this month-on-month doubling of sales continues, Mounjaro's revenue could cross Rs 500 crore by March, experts estimate. Reuters A combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, and a box of Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes and made by Lilly. US drugmaker Eli Lilly's weight-loss drug Mounjaro (tirzepatide) has crossed Rs 100 crore in sales in India in just four months of launch, making it one of the country's fastest-growing prescription brands ever by value. The drug clocked Rs 47-crore sales in July, double its June figure, according to data from prescriptions tracker PharmaTrac. If this month-on-month doubling of sales continues, Mounjaro's revenue could cross Rs 500 crore by March, experts estimate. After that, there could be a price erosion in the segment, as generic versions of rival GLP1 molecule semaglutide, branded as Wegovy by Danish drugmaker Novo Nordisk, are expected to flood the market. Drugs that have seen similar burgeoning growth in the past include some in the anti-diabetic category, such as Januvia (sitagliptin), Trajenta (linagliptin), Jardiance (empagliflozin), Forxiga (dapagliflozin), and Rybelsus (oral semaglutide). Wegovy, launched in early June, also saw a doubling of sales numbers with cumulative sales of the first two months at Rs 10 crore. 'Though Wegovy has a strong prescriber base because of Rybelsus (oral semaglutide), substantial promotion may be needed to reach the Mounjaro patient base for the injectable market,' said Sheetal Sapale, vice president, commercial, at PharmaTrac. Mounjaro, which was launched in late March, has so far garnered a significant patient base, selling about 160,000 units versus Wegovy's 5,000. 'As competition gets tough and branded generics come into the market, volume sales will be a major decider of who goes ahead in the race as this extent of value creation will be challenging,' Sapale said. Industry experts and doctors said the higher weight loss efficacy of 20-22% from Mounjaro compared to Wegovy's 16-18% and a lower price point make it more attractive to many patients. Wegovy is currently priced between Rs 17,345 to Rs 26,050 per pen-filled injection, which is a month's dose of four once-a-week shots. Mounjaro, which is also given on a weekly basis, is priced at Rs 14,000 to Rs 17,500 for a month's Shivane, diabetology and endocrinology consultant at Jaslok Hospital & Research Centre in Mumbai, said Mounjaro has captured a major share of the market so far due to their early launch and higher weight loss efficacy. 'Diabetes patients prefer Wegovy, while non-diabetes obese patients prefer Mounjaro,' he said. Apart from chronic weight management in obesity, Mounjaro is also indicated to improve glycaemic control in adults with type-2 diabetes mellitus, which is an additional benefit. Wegovy is used for obesity treatment and selectively in reduction in risk of major adverse cardiovascular events (MACE).
&w=3840&q=100)
Business Standard
4 hours ago
- Business Standard
Weighty issues: India's rush to make weight-loss drugs demands user caution
The global market for weight-loss drugs is estimated at $100 billion by the end of the decade premium Business Standard Editorial Comment Mumbai Listen to This Article Indian pharmaceutical companies are preparing for weighty gains when the patent for semaglutide, the active pharmaceutical ingredient (API) used in drugs for weight loss and the treatment of diabetes, lapses in 2026 in 100 countries, including India, Canada, and Brazil. Sold by Novo Nordisk under the brand names Ozempic and Wegovy, the drugs have proven to be blockbusters for the Danish pharma major, generating $25 billion in revenues in 2024 alone. No surprise, then, that Indian drugmakers have spotted a huge opportunity and are preparing to launch significantly cheaper generic versions of semaglutide. All the major names of the domestic
Time of India
5 hours ago
- Time of India
Weight-loss drug Mounjaro crosses Rs 100 crore sales in 4 months
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel US drugmaker Eli Lilly 's weight-loss drug Mounjaro (tirzepatide) has crossed Rs 100 crore in sales in India in just four months of launch, making it one of the country's fastest-growing prescription brands ever by drug clocked Rs 47-crore sales in July, double its June figure, according to data from prescriptions tracker this month-on-month doubling of sales continues, Mounjaro's revenue could cross Rs 500 crore by March, experts that, there could be a price erosion in the segment, as generic versions of rival GLP1 molecule semaglutide, branded as Wegovy by Danish drugmaker Novo Nordisk, are expected to flood the that have seen similar burgeoning growth in the past include some in the anti-diabetic category, such as Januvia (sitagliptin), Trajenta (linagliptin), Jardiance (empagliflozin), Forxiga (dapagliflozin), and Rybelsus (oral semaglutide).Wegovy, launched in early June, also saw a doubling of sales numbers with cumulative sales of the first two months at Rs 10 crore.'Though Wegovy has a strong prescriber base because of Rybelsus (oral semaglutide), substantial promotion may be needed to reach the Mounjaro patient base for the injectable market,' said Sheetal Sapale, vice president, commercial, at which was launched in late March, has so far garnered a significant patient base, selling about 160,000 units versus Wegovy's 5,000.'As competition gets tough and branded generics come into the market, volume sales will be a major decider of who goes ahead in the race as this extent of value creation will be challenging,' Sapale experts and doctors said the higher weight loss efficacy of 20-22% from Mounjaro compared to Wegovy's 16-18% and a lower price point make it more attractive to many is currently priced between Rs 17,345 to Rs 26,050 per pen-filled injection, which is a month's dose of four once-a-week shots. Mounjaro, which is also given on a weekly basis, is priced at Rs 14,000 to Rs 17,500 for a month's Shivane, diabetology and endocrinology consultant at Jaslok Hospital & Research Centre in Mumbai, said Mounjaro has captured a major share of the market so far due to their early launch and higher weight loss efficacy.'Diabetes patients prefer Wegovy, while non-diabetes obese patients prefer Mounjaro,' he from chronic weight management in obesity, Mounjaro is also indicated to improve glycaemic control in adults with type-2 diabetes mellitus, which is an additional benefit. Wegovy is used for obesity treatment and selectively in reduction in risk of major adverse cardiovascular events (MACE).
